Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Gastrointestinal symptoms such as nausea, bloating, or changes in appetite tend to be the most commonly reported effects during early stages of gradual treatment adjustment, and providers generally expect some of this during the initial phase
10.1161/01.ATV.0000110444.59568.56 114
A 2025 narrative review reached comparable conclusions on the compound's positioning within the broader incretin-class research peptide spectrum (PMID 40563436)
Theoretical risks Long-term or high-frequency use raises theoretical concerns about copper accumulation
It has documented antioxidant behaviour and has been shown to influence expression of genes associated with tissue remodelling
Universal health coverage and Global Health in Oncology, 17
